Clinical Trial Update: Study Evaluating Single Ascending Doses Of ILS-920 [Phase 1]

View source ↗

Summary

Phase 1 study evaluating single ascending doses of ILS-920 for Acute Ischemic Stroke has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Stroke

Drugs mentioned

• ILS-920

Snippet

Sponsor: Wyeth is now a wholly owned subsidiary of Pfizer | Conditions: Acute Ischemic Stroke | Phase 1 | Status: COMPLETED